TY - JOUR
T1 - Rituximab in indolent lymphoma
T2 - The single-agent pivotal trial
AU - McLaughlin, P.
AU - Hagemeister, F. B.
AU - Grillo-Lopez, A. J.
PY - 1999
Y1 - 1999
N2 - Rituximab (Rituxan; IDEC Pharmaceuticals, San Diego, CA, and Genentech, Inc, San Francisco, CA) is a chimeric anti-CD20 monoclonal antibody that targets mature B cells and most B-cell malignancies. Rituximab was the first monoclonal antibody to be approved for therapeutic use for any malignancy. Its approval was based on a single-agent pivotal trial in patients with indolent R-cell lymphoma, in which 166 patients were enrolled from 31 centers in the United States and Canada. The overall results of the trial have been previously reported; additional aspects of the trial (eg, pharmacokinetics) have been reported separately as well. The current report includes an update, expansion, and synthesis of data from the single-agent pivotal trial of rituximab.
AB - Rituximab (Rituxan; IDEC Pharmaceuticals, San Diego, CA, and Genentech, Inc, San Francisco, CA) is a chimeric anti-CD20 monoclonal antibody that targets mature B cells and most B-cell malignancies. Rituximab was the first monoclonal antibody to be approved for therapeutic use for any malignancy. Its approval was based on a single-agent pivotal trial in patients with indolent R-cell lymphoma, in which 166 patients were enrolled from 31 centers in the United States and Canada. The overall results of the trial have been previously reported; additional aspects of the trial (eg, pharmacokinetics) have been reported separately as well. The current report includes an update, expansion, and synthesis of data from the single-agent pivotal trial of rituximab.
UR - http://www.scopus.com/inward/record.url?scp=0032719758&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0032719758&partnerID=8YFLogxK
M3 - Article
C2 - 10561022
AN - SCOPUS:0032719758
SN - 0093-7754
VL - 26
SP - 79
EP - 87
JO - Seminars in oncology
JF - Seminars in oncology
IS - 5 SUPPL. 14
ER -